Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL

This study is testing a combination of three drugs — polatuzumab vedotin, rituximab, and orelabrutinib — for elderly or frail patients who have never been treated for a specific type of aggressive blood cancer called non-GCB diffuse large B-cell lymphoma (DLBCL). The regimen is designed to be effective but gentler than standard chemotherapy. **You may be eligible if...** - You are 60 years or older and have been assessed as frail or unfit for standard chemotherapy (via a geriatric assessment) - You have been newly diagnosed with non-GCB DLBCL (confirmed by biopsy) - You have measurable disease on imaging - You have not previously received lymphoma treatment (except corticosteroids) **You may NOT be eligible if...** - You have already received chemotherapy or other lymphoma treatments - Your DLBCL is the germinal center (GCB) subtype - You are fit enough for standard R-CHOP chemotherapy - You have serious organ problems Talk to your doctor to see if this trial is right for you.